Study to Evaluate the Efficacy and Safety of Toripalimab in Combination With Axitinib Versus Sunitinib Monotherapy in Advanced Renal Cell Cancer

NCT04394975 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

421

Enrollment

OTHER

Sponsor class

Conditions

Primary Disease: Unresectable or Metastatic Renal Cell Carcinoma Focus of the Study:PFS Assessed by IRC Per RECIST 1.1

Interventions

COMBINATION_PRODUCT: Biological : Toripalimab Drug: Axitinib
DRUG: sunitinib

Sponsor

Shanghai Junshi Bioscience Co., Ltd.